Most respiratory virus activity remains low overall across the EU/EEA. Influenza has returned to inter-seasonal levels. COVID 19 circulation is also very low. RSV activity is elevated but decreasing. Peak levels having passed in most countries.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 April 2026, and includes updates on respiratory virus epidemiology in the EU/EEA, measles, zika, and chikungunya.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4-10 April 2026, and includes updates on avian influenza, dengue, and an overview of respiratory virus epidemiology in the EU/EEA.
Most respiratory virus activity remains low overall across the EU/EEA. Influenza and COVID 19 circulation are low or continuing to decline. RSV activity remains elevated, with early indications of a gradual decline.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 March-3 April 2026 and includes updates on SARS-CoV-2 variant classification, Middle East respiratory syndrome coronavirus (MERS-CoV), cholera, HIV, and avian influenza.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21–27 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya, dengue, avian influenza, invasive meningococcal disease, aedes aegypti detection in Luxembourg, and measles.
Most respiratory viruses are declining across the EU/EEA: Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity is low. RSV activity remains elevated, with children under five years the most affected.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14 -20 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, mass gathering monitoring, avian influenza, dengue, serious adverse events to IXCHIQ chikungunya virus disease vaccine, and invasive meningococcal disease.
Respiratory virus trends across the EU/EEA continue to show early signs of decline. RSV circulation remains high, with children under five years the most affected. Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity remains low.